Severe hepatitis due to Atrium. -

Severe hepatitis due to Atrium.

Abstract	(1) Atrium, a combination of difebarbamate, febarbamate and phenobarbital first marketed in France more than 30 years ago, carries a risk of hepatitis. (2) Despite restrictions on its indications and treatment duration introduced in 1997, cases of severe liver damage have continued to be notified in France. (3) Benzodiazepines are the reference drugs for alcohol withdrawal. Carbamates and barbiturates are no more effective than benzodiazepines, and carry a higher risk of adverse effects. (4) The recent decision to withdraw Atrium from the market was long awaited.
Authors
Journal	Prescrire international (Prescrire Int) Vol. 10 Issue 55 Pg. 150 (Oct 2001) ISSN: 1167-7422 [Print] France
PMID	11824432 (Publication Type: Journal Article)
Chemical References	Barbiturates Drug Combinations
Topics	Barbiturates (adverse effects, therapeutic use) Chemical and Drug Induced Liver Injury (etiology) Drug Combinations Drug and Narcotic Control France Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!